| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 43 | 2025 | 1134 | 9.890 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 43 | 2024 | 400 | 7.360 |
Why?
|
| Carcinoma, Hepatocellular | 26 | 2026 | 976 | 5.110 |
Why?
|
| End Stage Liver Disease | 23 | 2025 | 193 | 4.630 |
Why?
|
| Liver Neoplasms | 27 | 2026 | 1367 | 4.600 |
Why?
|
| Hepatitis C, Chronic | 19 | 2023 | 356 | 4.370 |
Why?
|
| Hepatitis C | 16 | 2026 | 381 | 4.070 |
Why?
|
| Liver Diseases, Alcoholic | 10 | 2023 | 62 | 3.250 |
Why?
|
| Liver Cirrhosis | 36 | 2026 | 901 | 3.210 |
Why?
|
| Tissue and Organ Procurement | 8 | 2025 | 252 | 2.630 |
Why?
|
| Antiviral Agents | 18 | 2023 | 805 | 2.500 |
Why?
|
| Hepacivirus | 13 | 2023 | 273 | 2.360 |
Why?
|
| Waiting Lists | 14 | 2025 | 249 | 2.210 |
Why?
|
| Fatty Liver | 11 | 2026 | 221 | 2.110 |
Why?
|
| Coronavirus Infections | 5 | 2020 | 339 | 1.930 |
Why?
|
| Pneumonia, Viral | 5 | 2020 | 349 | 1.930 |
Why?
|
| Tissue Donors | 10 | 2025 | 503 | 1.820 |
Why?
|
| Nutrition Surveys | 23 | 2025 | 332 | 1.720 |
Why?
|
| United States | 64 | 2026 | 12009 | 1.580 |
Why?
|
| Hepatitis, Alcoholic | 6 | 2025 | 30 | 1.560 |
Why?
|
| Gastrointestinal Diseases | 3 | 2021 | 339 | 1.500 |
Why?
|
| Betacoronavirus | 5 | 2020 | 273 | 1.400 |
Why?
|
| Humans | 150 | 2026 | 130534 | 1.280 |
Why?
|
| Retrospective Studies | 48 | 2025 | 17653 | 1.170 |
Why?
|
| Pandemics | 15 | 2024 | 1115 | 1.150 |
Why?
|
| Risk Factors | 38 | 2025 | 11012 | 1.100 |
Why?
|
| Hospitalization | 13 | 2024 | 1943 | 1.100 |
Why?
|
| Graft Survival | 9 | 2025 | 459 | 1.040 |
Why?
|
| Middle Aged | 59 | 2026 | 28424 | 1.040 |
Why?
|
| Organ Transplantation | 2 | 2020 | 169 | 1.020 |
Why?
|
| Adult | 59 | 2026 | 31121 | 1.010 |
Why?
|
| Bile Duct Neoplasms | 2 | 2025 | 130 | 1.000 |
Why?
|
| Hepatitis B, Chronic | 5 | 2023 | 84 | 0.990 |
Why?
|
| Prevalence | 23 | 2026 | 2692 | 0.950 |
Why?
|
| Klatskin Tumor | 1 | 2025 | 10 | 0.920 |
Why?
|
| Alcohol Drinking | 3 | 2023 | 341 | 0.860 |
Why?
|
| Aged | 37 | 2026 | 20899 | 0.850 |
Why?
|
| Liver | 11 | 2025 | 1788 | 0.850 |
Why?
|
| Elasticity Imaging Techniques | 6 | 2024 | 157 | 0.830 |
Why?
|
| Male | 70 | 2026 | 64598 | 0.830 |
Why?
|
| Mortality | 4 | 2021 | 264 | 0.800 |
Why?
|
| Transplant Recipients | 3 | 2021 | 229 | 0.800 |
Why?
|
| Female | 69 | 2026 | 70563 | 0.770 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2023 | 51 | 0.770 |
Why?
|
| Length of Stay | 8 | 2025 | 1412 | 0.740 |
Why?
|
| Liver Failure | 3 | 2017 | 98 | 0.740 |
Why?
|
| Cause of Death | 15 | 2025 | 502 | 0.730 |
Why?
|
| Proton Pump Inhibitors | 3 | 2020 | 275 | 0.730 |
Why?
|
| Coinfection | 2 | 2023 | 187 | 0.690 |
Why?
|
| Healthcare Disparities | 3 | 2022 | 518 | 0.690 |
Why?
|
| Drug Overdose | 2 | 2020 | 73 | 0.690 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2025 | 236 | 0.680 |
Why?
|
| Liver Cirrhosis, Biliary | 2 | 2020 | 88 | 0.670 |
Why?
|
| Severity of Illness Index | 13 | 2025 | 3040 | 0.660 |
Why?
|
| Hepatic Encephalopathy | 5 | 2025 | 83 | 0.620 |
Why?
|
| Alcohol-Related Disorders | 1 | 2019 | 35 | 0.610 |
Why?
|
| Gastrointestinal Tract | 1 | 2021 | 209 | 0.600 |
Why?
|
| Gastrectomy | 2 | 2017 | 104 | 0.590 |
Why?
|
| Liver Diseases | 5 | 2023 | 378 | 0.590 |
Why?
|
| Probiotics | 1 | 2021 | 226 | 0.570 |
Why?
|
| Hepatitis C Antibodies | 1 | 2018 | 27 | 0.560 |
Why?
|
| DNA, Viral | 2 | 2018 | 447 | 0.530 |
Why?
|
| Diabetes Mellitus | 6 | 2024 | 888 | 0.530 |
Why?
|
| Mesenteric Veins | 1 | 2017 | 14 | 0.520 |
Why?
|
| Shock, Hemorrhagic | 1 | 2017 | 50 | 0.500 |
Why?
|
| Time Factors | 13 | 2024 | 6168 | 0.500 |
Why?
|
| Hospital Mortality | 4 | 2020 | 1059 | 0.500 |
Why?
|
| Portal Vein | 1 | 2017 | 84 | 0.500 |
Why?
|
| Skilled Nursing Facilities | 1 | 2016 | 5 | 0.490 |
Why?
|
| Transplants | 1 | 2016 | 38 | 0.480 |
Why?
|
| Treatment Outcome | 19 | 2025 | 12854 | 0.480 |
Why?
|
| Secondary Prevention | 1 | 2017 | 216 | 0.470 |
Why?
|
| Postoperative Complications | 3 | 2025 | 3126 | 0.470 |
Why?
|
| Proportional Hazards Models | 9 | 2025 | 1409 | 0.460 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 164 | 0.450 |
Why?
|
| Cardiovascular Diseases | 7 | 2025 | 2111 | 0.450 |
Why?
|
| Health Care Costs | 4 | 2024 | 407 | 0.440 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2019 | 298 | 0.430 |
Why?
|
| HIV Infections | 3 | 2025 | 2047 | 0.430 |
Why?
|
| Hospital Costs | 1 | 2016 | 187 | 0.430 |
Why?
|
| Registries | 5 | 2025 | 1614 | 0.420 |
Why?
|
| Databases, Factual | 8 | 2022 | 1234 | 0.420 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 832 | 0.400 |
Why?
|
| Colonic Neoplasms | 1 | 2016 | 262 | 0.390 |
Why?
|
| Acute-On-Chronic Liver Failure | 2 | 2025 | 74 | 0.380 |
Why?
|
| Risk Assessment | 13 | 2024 | 3687 | 0.380 |
Why?
|
| Hepatitis, Viral, Human | 2 | 2023 | 44 | 0.380 |
Why?
|
| HIV | 2 | 2025 | 174 | 0.380 |
Why?
|
| Cholangiocarcinoma | 3 | 2024 | 126 | 0.370 |
Why?
|
| Cholangitis, Sclerosing | 2 | 2025 | 75 | 0.370 |
Why?
|
| Biliary Tract Neoplasms | 2 | 2024 | 28 | 0.370 |
Why?
|
| Young Adult | 13 | 2025 | 10036 | 0.360 |
Why?
|
| Patient Readmission | 3 | 2020 | 441 | 0.350 |
Why?
|
| Cohort Studies | 8 | 2025 | 5048 | 0.350 |
Why?
|
| Laparoscopy | 1 | 2017 | 537 | 0.350 |
Why?
|
| Incidence | 8 | 2026 | 3336 | 0.350 |
Why?
|
| Cross-Sectional Studies | 11 | 2025 | 3815 | 0.340 |
Why?
|
| Ascites | 4 | 2025 | 99 | 0.340 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 1069 | 0.340 |
Why?
|
| Aged, 80 and over | 10 | 2024 | 6772 | 0.340 |
Why?
|
| Health Policy | 2 | 2025 | 234 | 0.320 |
Why?
|
| Hypothyroidism | 2 | 2020 | 71 | 0.290 |
Why?
|
| Disease Progression | 7 | 2025 | 2192 | 0.280 |
Why?
|
| Inpatients | 4 | 2020 | 561 | 0.270 |
Why?
|
| Health Status Disparities | 3 | 2020 | 281 | 0.260 |
Why?
|
| Esophageal and Gastric Varices | 2 | 2025 | 72 | 0.250 |
Why?
|
| Recurrence | 3 | 2021 | 1483 | 0.250 |
Why?
|
| Kidney Transplantation | 2 | 2025 | 553 | 0.250 |
Why?
|
| Opioid-Related Disorders | 2 | 2021 | 352 | 0.240 |
Why?
|
| Cost of Illness | 3 | 2026 | 297 | 0.230 |
Why?
|
| Metabolic Diseases | 2 | 2024 | 141 | 0.220 |
Why?
|
| Preoperative Period | 3 | 2020 | 90 | 0.220 |
Why?
|
| Cholangitis | 1 | 2025 | 38 | 0.220 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2025 | 744 | 0.220 |
Why?
|
| Troponin | 1 | 2025 | 69 | 0.220 |
Why?
|
| Intention to Treat Analysis | 1 | 2024 | 59 | 0.220 |
Why?
|
| Depression | 3 | 2023 | 1316 | 0.210 |
Why?
|
| Pulse Wave Analysis | 1 | 2024 | 48 | 0.210 |
Why?
|
| Donor Selection | 1 | 2024 | 60 | 0.210 |
Why?
|
| Hepatitis A | 1 | 2024 | 28 | 0.210 |
Why?
|
| Organ Preservation | 1 | 2025 | 62 | 0.210 |
Why?
|
| Republic of Korea | 1 | 2024 | 45 | 0.200 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2026 | 148 | 0.200 |
Why?
|
| Telemedicine | 2 | 2023 | 525 | 0.200 |
Why?
|
| Perfusion | 1 | 2025 | 209 | 0.200 |
Why?
|
| Age Distribution | 3 | 2019 | 421 | 0.200 |
Why?
|
| Vascular Stiffness | 1 | 2024 | 76 | 0.200 |
Why?
|
| Neoadjuvant Therapy | 1 | 2025 | 400 | 0.190 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2026 | 205 | 0.190 |
Why?
|
| Policy | 1 | 2023 | 39 | 0.190 |
Why?
|
| Adolescent | 6 | 2024 | 20879 | 0.190 |
Why?
|
| Adenocarcinoma | 2 | 2023 | 970 | 0.190 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2025 | 331 | 0.190 |
Why?
|
| Opiate Substitution Treatment | 2 | 2021 | 65 | 0.190 |
Why?
|
| California | 2 | 2020 | 127 | 0.180 |
Why?
|
| Glucocorticoids | 1 | 2025 | 347 | 0.180 |
Why?
|
| Chi-Square Distribution | 3 | 2018 | 562 | 0.180 |
Why?
|
| Integrases | 1 | 2023 | 157 | 0.180 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2021 | 28 | 0.170 |
Why?
|
| Hepatitis B | 1 | 2023 | 170 | 0.170 |
Why?
|
| Prebiotics | 1 | 2021 | 29 | 0.170 |
Why?
|
| Viremia | 1 | 2022 | 130 | 0.170 |
Why?
|
| Alcohol Abstinence | 1 | 2021 | 15 | 0.170 |
Why?
|
| Health Care Rationing | 1 | 2021 | 58 | 0.170 |
Why?
|
| Cholestasis | 1 | 2023 | 170 | 0.170 |
Why?
|
| Gallbladder Neoplasms | 1 | 2021 | 15 | 0.170 |
Why?
|
| Tacrolimus | 1 | 2021 | 100 | 0.170 |
Why?
|
| Hypernatremia | 1 | 2021 | 32 | 0.170 |
Why?
|
| Military Personnel | 1 | 2023 | 218 | 0.170 |
Why?
|
| Age Factors | 4 | 2024 | 2818 | 0.160 |
Why?
|
| Hyponatremia | 1 | 2021 | 73 | 0.160 |
Why?
|
| Hepatitis B virus | 2 | 2023 | 133 | 0.160 |
Why?
|
| Healthy Lifestyle | 1 | 2020 | 33 | 0.160 |
Why?
|
| Acute Kidney Injury | 2 | 2025 | 703 | 0.160 |
Why?
|
| Vaccines, Synthetic | 1 | 2021 | 324 | 0.160 |
Why?
|
| Dysbiosis | 1 | 2021 | 144 | 0.160 |
Why?
|
| Sarcopenia | 1 | 2021 | 56 | 0.160 |
Why?
|
| Peritonitis | 2 | 2017 | 75 | 0.160 |
Why?
|
| Prediabetic State | 1 | 2021 | 68 | 0.160 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 1376 | 0.160 |
Why?
|
| Exercise | 3 | 2021 | 891 | 0.160 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2020 | 81 | 0.160 |
Why?
|
| Digestive System Diseases | 1 | 2020 | 22 | 0.160 |
Why?
|
| Biliary Atresia | 1 | 2023 | 223 | 0.160 |
Why?
|
| Thyroid Gland | 1 | 2020 | 96 | 0.150 |
Why?
|
| Follow-Up Studies | 4 | 2025 | 5184 | 0.150 |
Why?
|
| Causality | 1 | 2019 | 89 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1266 | 0.150 |
Why?
|
| Methadone | 1 | 2020 | 135 | 0.150 |
Why?
|
| Entamoebiasis | 1 | 2019 | 2 | 0.150 |
Why?
|
| Fibrosis | 4 | 2024 | 424 | 0.150 |
Why?
|
| Entamoeba histolytica | 1 | 2019 | 10 | 0.150 |
Why?
|
| Marijuana Smoking | 1 | 2019 | 30 | 0.140 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2020 | 228 | 0.140 |
Why?
|
| Phenols | 1 | 2019 | 73 | 0.140 |
Why?
|
| Colonic Diseases | 1 | 2019 | 38 | 0.140 |
Why?
|
| Drug Monitoring | 1 | 2021 | 291 | 0.140 |
Why?
|
| Benzhydryl Compounds | 1 | 2019 | 79 | 0.140 |
Why?
|
| Marijuana Abuse | 1 | 2019 | 52 | 0.140 |
Why?
|
| Sex Distribution | 1 | 2019 | 318 | 0.130 |
Why?
|
| Metabolic Syndrome | 1 | 2021 | 367 | 0.130 |
Why?
|
| Analgesics, Opioid | 2 | 2021 | 542 | 0.130 |
Why?
|
| Rifamycins | 1 | 2017 | 18 | 0.130 |
Why?
|
| Global Burden of Disease | 1 | 2017 | 37 | 0.130 |
Why?
|
| Licensed Practical Nurses | 1 | 2017 | 1 | 0.130 |
Why?
|
| Bacterial Infections | 2 | 2017 | 327 | 0.130 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 653 | 0.130 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2021 | 324 | 0.130 |
Why?
|
| Sofosbuvir | 1 | 2017 | 20 | 0.130 |
Why?
|
| Hepatorenal Syndrome | 1 | 2017 | 31 | 0.130 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2017 | 31 | 0.130 |
Why?
|
| Carbamates | 1 | 2017 | 64 | 0.130 |
Why?
|
| Thrombophilia | 1 | 2017 | 41 | 0.130 |
Why?
|
| Nutritional Support | 1 | 2017 | 67 | 0.120 |
Why?
|
| United States Health Resources and Services Administration | 1 | 2016 | 3 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 1 | 2023 | 739 | 0.120 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 209 | 0.120 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2018 | 266 | 0.120 |
Why?
|
| Clostridium Infections | 1 | 2020 | 249 | 0.120 |
Why?
|
| Medically Underserved Area | 1 | 2017 | 86 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2023 | 3351 | 0.120 |
Why?
|
| RNA, Messenger | 1 | 2021 | 2544 | 0.120 |
Why?
|
| Heparin | 1 | 2017 | 206 | 0.120 |
Why?
|
| Income | 1 | 2016 | 138 | 0.120 |
Why?
|
| Nutritional Status | 1 | 2017 | 298 | 0.110 |
Why?
|
| Computed Tomography Angiography | 1 | 2017 | 217 | 0.110 |
Why?
|
| Malnutrition | 1 | 2017 | 156 | 0.110 |
Why?
|
| Survival Analysis | 4 | 2022 | 1480 | 0.110 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 1171 | 0.110 |
Why?
|
| Educational Status | 1 | 2016 | 278 | 0.110 |
Why?
|
| Lymph Node Excision | 1 | 2016 | 158 | 0.110 |
Why?
|
| Insurance, Health | 1 | 2016 | 146 | 0.110 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 293 | 0.110 |
Why?
|
| Health Resources | 1 | 2016 | 130 | 0.110 |
Why?
|
| Heterozygote | 1 | 2017 | 721 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 787 | 0.100 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2016 | 259 | 0.100 |
Why?
|
| Survival Rate | 4 | 2020 | 2109 | 0.100 |
Why?
|
| Lymph Nodes | 1 | 2016 | 357 | 0.100 |
Why?
|
| Health Services Accessibility | 2 | 2017 | 708 | 0.100 |
Why?
|
| Logistic Models | 3 | 2025 | 1796 | 0.100 |
Why?
|
| Allografts | 2 | 2025 | 220 | 0.090 |
Why?
|
| Anticoagulants | 1 | 2017 | 601 | 0.090 |
Why?
|
| Kidney | 1 | 2019 | 1280 | 0.090 |
Why?
|
| Veterans | 1 | 2023 | 1756 | 0.090 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2016 | 503 | 0.090 |
Why?
|
| Decision Making | 1 | 2016 | 714 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2023 | 6424 | 0.080 |
Why?
|
| Kidney Failure, Chronic | 1 | 2019 | 930 | 0.080 |
Why?
|
| Comorbidity | 3 | 2023 | 1589 | 0.080 |
Why?
|
| Morbidity | 2 | 2023 | 256 | 0.080 |
Why?
|
| Prognosis | 4 | 2023 | 4866 | 0.080 |
Why?
|
| Hepatitis B Surface Antigens | 2 | 2023 | 60 | 0.080 |
Why?
|
| Observational Studies as Topic | 2 | 2023 | 103 | 0.080 |
Why?
|
| ROC Curve | 2 | 2023 | 613 | 0.080 |
Why?
|
| Medicaid | 2 | 2023 | 268 | 0.080 |
Why?
|
| Stomach Neoplasms | 1 | 2016 | 572 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2025 | 1262 | 0.080 |
Why?
|
| Chronic Disease | 3 | 2018 | 1243 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2062 | 0.070 |
Why?
|
| Censuses | 2 | 2019 | 9 | 0.070 |
Why?
|
| Child | 3 | 2024 | 26237 | 0.070 |
Why?
|
| Sex Factors | 2 | 2024 | 1348 | 0.070 |
Why?
|
| Biopsy | 2 | 2023 | 1229 | 0.070 |
Why?
|
| Linear Models | 2 | 2020 | 687 | 0.070 |
Why?
|
| Ultrasonography | 2 | 2024 | 942 | 0.070 |
Why?
|
| SEER Program | 2 | 2021 | 213 | 0.070 |
Why?
|
| Quality of Life | 1 | 2017 | 2076 | 0.070 |
Why?
|
| Body Mass Index | 2 | 2024 | 1704 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2021 | 1209 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 2580 | 0.060 |
Why?
|
| Renal Dialysis | 2 | 2025 | 948 | 0.050 |
Why?
|
| North America | 1 | 2025 | 255 | 0.050 |
Why?
|
| Prednisolone | 1 | 2025 | 73 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2018 | 554 | 0.050 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2024 | 30 | 0.050 |
Why?
|
| Primary Graft Dysfunction | 1 | 2025 | 41 | 0.050 |
Why?
|
| Agent Orange | 1 | 2023 | 3 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 1165 | 0.050 |
Why?
|
| Reperfusion Injury | 1 | 2025 | 107 | 0.050 |
Why?
|
| Neoplasms | 1 | 2019 | 2994 | 0.050 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2023 | 82 | 0.050 |
Why?
|
| Mutation | 1 | 2017 | 6059 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 2298 | 0.050 |
Why?
|
| Electronic Health Records | 2 | 2023 | 843 | 0.050 |
Why?
|
| Food Supply | 1 | 2024 | 93 | 0.050 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2023 | 103 | 0.050 |
Why?
|
| Living Donors | 1 | 2023 | 110 | 0.050 |
Why?
|
| Hand Strength | 1 | 2022 | 58 | 0.050 |
Why?
|
| Muscle Strength | 1 | 2022 | 77 | 0.050 |
Why?
|
| Ethanol | 1 | 2023 | 167 | 0.050 |
Why?
|
| Acute Disease | 1 | 2025 | 1152 | 0.040 |
Why?
|
| Ontario | 1 | 2021 | 85 | 0.040 |
Why?
|
| Estradiol | 1 | 2023 | 460 | 0.040 |
Why?
|
| alpha-Fetoproteins | 1 | 2022 | 125 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2022 | 194 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2025 | 540 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2021 | 120 | 0.040 |
Why?
|
| Respiratory Protective Devices | 1 | 2020 | 6 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2024 | 477 | 0.040 |
Why?
|
| Animals | 1 | 2021 | 33739 | 0.040 |
Why?
|
| Sodium | 1 | 2021 | 280 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 2020 | 80 | 0.040 |
Why?
|
| Obesity | 2 | 2024 | 2416 | 0.040 |
Why?
|
| Platelet Count | 1 | 2020 | 139 | 0.040 |
Why?
|
| Death Certificates | 1 | 2019 | 10 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2020 | 153 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2023 | 718 | 0.040 |
Why?
|
| Protective Factors | 1 | 2019 | 90 | 0.040 |
Why?
|
| Paromomycin | 1 | 2019 | 5 | 0.040 |
Why?
|
| Weight Loss | 1 | 2023 | 535 | 0.040 |
Why?
|
| Thyrotropin | 1 | 2018 | 49 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 99 | 0.040 |
Why?
|
| Antiprotozoal Agents | 1 | 2019 | 41 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 723 | 0.030 |
Why?
|
| Testosterone | 1 | 2023 | 528 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 416 | 0.030 |
Why?
|
| Myositis | 1 | 2019 | 84 | 0.030 |
Why?
|
| Sustained Virologic Response | 1 | 2018 | 46 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2020 | 462 | 0.030 |
Why?
|
| Hepatitis B e Antigens | 1 | 2016 | 14 | 0.030 |
Why?
|
| Patient Portals | 1 | 2017 | 19 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2020 | 401 | 0.030 |
Why?
|
| Computer Security | 1 | 2017 | 32 | 0.030 |
Why?
|
| Markov Chains | 1 | 2017 | 101 | 0.030 |
Why?
|
| Nutrition Assessment | 1 | 2017 | 126 | 0.030 |
Why?
|
| Colonoscopy | 1 | 2019 | 241 | 0.030 |
Why?
|
| Advanced Practice Nursing | 1 | 2016 | 9 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2018 | 233 | 0.030 |
Why?
|
| Immunization, Passive | 1 | 2016 | 120 | 0.030 |
Why?
|
| Confidentiality | 1 | 2017 | 108 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 2018 | 238 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2017 | 267 | 0.030 |
Why?
|
| Safety-net Providers | 1 | 2017 | 92 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2018 | 293 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 566 | 0.030 |
Why?
|
| Biomarkers | 1 | 2025 | 3366 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 313 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2018 | 356 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2019 | 563 | 0.030 |
Why?
|
| Health Personnel | 1 | 2020 | 539 | 0.030 |
Why?
|
| Palliative Care | 1 | 2019 | 442 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1484 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2017 | 709 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 425 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2021 | 980 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2018 | 1319 | 0.030 |
Why?
|
| Patient Selection | 1 | 2018 | 724 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 1457 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 511 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2022 | 1581 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1287 | 0.020 |
Why?
|
| Anxiety | 1 | 2020 | 1010 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1874 | 0.020 |
Why?
|
| Algorithms | 1 | 2020 | 1669 | 0.020 |
Why?
|
| Cesarean Section | 1 | 2016 | 426 | 0.020 |
Why?
|
| Diet | 1 | 2020 | 1113 | 0.020 |
Why?
|
| Communication | 1 | 2017 | 540 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2020 | 8606 | 0.020 |
Why?
|
| Infant | 1 | 2020 | 13295 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2020 | 15029 | 0.010 |
Why?
|
| Pregnancy | 1 | 2016 | 7475 | 0.010 |
Why?
|